Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Research and Innovation Action · Running

AutoPiX Imaging for Patient Benefit in Arthritis

Coordinator
Medizinische Universitaet Wien, Austria
Runs
1 November 2024 to 31 October 2029
Status
Running
EU funding
€10.7m
Total cost
€21.2m
Partners
20 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101194766

What the project is doing

In the project's own words, from its summary on CORDIS.

Patients at risk or diagnosed with arthritis are constantly assessed by innovative imaging techniques to document the onset or progression of their disease. However, despite their impressive abundance and resolution, these images lack the analysis and interpretation tools necessary to deliver unbiased and precise diagnosis, monitoring and prognosis to the patients. Additionally, some key advanced imaging methodologies such as ultrasound are hardly accessible to most of patients, urging improvements of more accessible imaging methods.

The AutoPiX project is an ambitious international multi-stakeholder effort led jointly and synergistically by academic and industry partners to achieve breakthroughs in both the applicability and harnessing of imaging technologies for the benefit of patients by creating new powerful analysis and decision tools. We will first generate tools to transform unstructured images into quantitative biomarkers using artificial intelligence (AI) and machine learning (ML) models, and validate them clinically for their diagnosis, monitoring and prognosis power.

This will considerably increase the utility of imaging biomarkers for arthritis and bring them to the same level as laboratory biomarkers. In parallel we will develop accessible imaging strategies such as remote monitoring and robotic-powered point-of-care ultrasound exams for patients to mitigate the often-observed shortage of qualified personnel in real world settings. To achieve this, we will improve the precision and interpretability of these methods and further validate them with clinical, molecular and histological analyses.

Our consortium is built on multi-disciplinarity and the constant synergistic interaction of all the actors of arthritis care: rheumatologists, radiologists, patients, researchers, regulators, industries and small- and medium sized enterprises (SMEs). On the long term, AutoPiX will create new clinically-validated methods to achieve a/ more precise, accessible and effective diagnosis, b/ shortened and better-tailored treatment paths and c/ improved treatment response assessments and outcome prediction for patients with arthritis.

Who is involved

OrganisationCityCountryRole
Medizinische Universitaet WienWienAustriaCoordinator
Ages - Osterreichische Agentur Fur Gesundheit Und Ernahrungssicherheit GmbHWienAustriaParticipant
Janssen Pharmaceutica NVBeerseBelgiumParticipant
Ucb BiopharmaBruxelles / BrusselBelgiumParticipant
Centre Hospitalier Universitaire VaudoisLausanneSwitzerlandAssociatedpartner
European Alliance of Associations for RheumatologyZurichSwitzerlandAssociatedpartner
Moonlake Immunotherapeutics AGZugSwitzerlandParticipant
Novartis Pharma AGBaselSwitzerlandParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Eurice European Research and Project Office GmbHSt IngbertGermanyParticipant
Ruhr-Universitaet BochumBochumGermanyParticipant
Region HovedstadenHillerodDenmarkParticipant
Ropca ApsOdenseDenmarkParticipant
Instituto De Salud Musculoesqueletica SLMadridSpainParticipant
Janssen Cilag SAMadridSpainAssociatedpartner
Singularity Biomed, S.L.Sant Cugat Del VallèsSpainParticipant
Scienta LabGif-Sur-YvetteFranceParticipant
Collective Minds Radiology ABDanderydSwedenParticipant
Queen Mary University of LondonLondonUnited KingdomParticipant
Janssen Research & Development, LLCRaritanUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI